Citadel Advisors
TFFP

Citadel Advisors’s TFF Pharmaceuticals, Inc. Common Stock TFFP Stock Holding History

Citadel Advisors’s Portfolio TFFP Stock Details TFFP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-896
Closed -$10.5K – 15322
2023
Q2 		$10.5K Sell
896
-952
-52% -$13.7K ﹤0.01% 13197
2023
Q1 		$31.7K Sell
1,848
-508
-22% -$11K ﹤0.01% 12678
2022
Q4 		$61.8K Buy
2,356
+1,092
+86% +$51.8K ﹤0.01% 11877
2022
Q3 		$128K Sell
1,264
-816
-39% -$110K ﹤0.01% 10872
2022
Q2 		$294K Sell
2,080
-80
-4% -$11.2K ﹤0.01% 9849
2022
Q1 		$341K Sell
2,160
-52
-2% -$8.4K ﹤0.01% 10305
2021
Q4 		$491K Buy
2,212
+1,312
+146% +$254K ﹤0.01% 9744
2021
Q3 		$174K Sell
900
-204
-18% -$43.3K ﹤0.01% 12177
2021
Q2 		$265K Sell
1,104
-1,972
-64% -$541K ﹤0.01% 11574
2021
Q1 		$1.04M Buy
3,076
+1,920
+166% +$781K ﹤0.01% 8005
2020
Q4 		$414K Sell
1,156
-516
-31% -$199K ﹤0.01% 8494
2020
Q3 		$772K Buy
+1,672
New +$472K ﹤0.01% 6512

Other funds holding TFFP

SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

Citadel Advisors's TFFP Position: Q4 2024 in Review

Citadel Advisors sold out of TFF Pharmaceuticals, Inc. Common Stock (TFFP) in Q4 2024, closing a stake of 13,579 shares — an estimated $27.3K sold.

Citadel Advisors first reported a position in TFFP in Q3 2020 and held it in 12 quarters. The position peaked at $1.32M in Q3 2020. 4 funds tracked by Wall St. Rank hold TFFP as of Q4 2024.

  • Citadel Advisors reported no remaining TFF Pharmaceuticals, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
  • Citadel Advisors sold 13,579 TFF Pharmaceuticals, Inc. Common Stock shares in Q4 2024, an estimated $27.3K.
  • Citadel Advisors first reported a position in TFF Pharmaceuticals, Inc. Common Stock in Q3 2020 and held it in 12 quarters.
  • Citadel Advisors's TFF Pharmaceuticals, Inc. Common Stock position peaked at $1.32M in Q3 2020.
  • 4 funds tracked by Wall St. Rank held TFF Pharmaceuticals, Inc. Common Stock as of Q4 2024.

Based on Citadel Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.